The first step in the management of patients with metastatic well-differentiated ANENs is to determine factors that may impact therapeutic strategies such as tumor grade, site of metastatic disease (hepatic vs. extra-hepatic), tumor burden, and the status of somatostatin expression [91,92]. This evidence concerns the gene SST and neoplasm.